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INTRODUCTION 
 
Immunoglobulin G is the most common antibody class 
circulating in human blood [1]. It mediates interactions 
between antigens and the immune system [2]. There are 
four IgG subclasses present in plasma, which differ in the 
constant region of the molecule: IgG1, IgG2, IgG3 and 
IgG4 [3]. Each subclass has distinctive features and 
functions, such as pronounced affinity for certain types of 
antigens, formation of immune complexes, complement 
activation, interactions with effector cells, half-life and 
placental transport [2]. Every IgG molecule contains 
covalently attached N-linked glycans which are essential 
for some of its functions [4]. 
 
Glycosylation is a co- and post-translational 
modification which is orchestrated by a complex 
biosynthetic pathway [5]. IgG contains a conserved N-
glycosylation site on Asn297 residue within its fragment 
crystallizable (Fc) region, on each of the two identical 
heavy chains [6]. Glycans attached to IgG are mainly of 
a complex biantennary type, with the core structure 
consisting of four N-acetylglucosamines (GlcNAc) and 
three mannoses. Different glycan moieties such as 
bisecting GlcNAc, galactose, sialic acid and fucose can 
be attached to this core [4]. IgG shows a high degree of 
diversity in glycosylation, with each of the four IgG 
subclasses displaying a distinctive glycome composition 
[7]. Also, each of the heavy chains of the same 
molecule can carry different glycans, creating a large 
repertoire of possible IgG glycoforms [8]. Finally, in 
15-20% of cases, an additional N-glycosylation site 
appears within variable region of antigen-binding 
fragment (Fab), as a result of somatic hypermutation 
events during affinity maturation [9]. 
 
Many IgG functions are achieved through interactions 
with receptors on immune cells and complement 
proteins. Fc glycans affect immunoglobulin 
conformation, which, in turn, defines binding affinity for 
Fc gamma receptors (FcγRs) on effector cells and 
complement, leading to alterations in effector functions 
[1, 10, 11]. Furthermore, IgG galactosylation level has an 
extensive effect on its inflammatory potential [12]. 
Namely, agalactosylated IgG has increased inflammatory 
potential through activation of alternative complement 
pathway, while on the other hand, high level of galactose 
is necessary for activation of anti-inflammatory cascade 
through interactions with FcγRIIB and inhibition of the 
inflammatory activity of C5a complement component 
[13–16]. However, there are also reports suggesting pro-
inflammatory action of highly galactosylated IgG. 
Terminal IgG galactosylation is required for increased 
binding to activating Fc gamma receptors and therefore 
activation of antibody-dependent cellular cytotoxicity 
(ADCC) [17]. Also, terminal galactoses are necessary for 
C1q complement component binding and activation of 
complement-dependent cytotoxicity (CDC) [18]. 
Attachment of other sugar moieties affects antibody 
properties as well. Namely, presence of fucose attached 
to the first N-acetylglucosamine, i.e. core fucose, 
decreases ADCC activity, while the presence of bisecting 
GlcNAc increases binding affinity for activating Fcγ 
receptors [19]. Terminal sialic acids appear to contribute 
to enhanced anti-inflammatory activity of intravenous 
immunoglobulin (IVIg) [20]. Although a subject to 
debate, proposed mechanisms include reduced affinity of 
sialylated IgG for activating FcγRs, and increased 
recognition by lectin receptors and complement 
component C1q [21, 22]. 
 
There is a prominent inter-individual variability of the 
total IgG N-glycome, which is under strong influence of 
numerous genes and environmental factors [23]. Average 
IgG glycome heritability is estimated to approximately 
50%, while the remaining variability can be mostly 
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attributed to environmental factors [23–25]. Prominent 
changes in the IgG N-glycome composition were found in 
several diseases. In different autoimmune and alloimmune 
disorders, cancers and infectious diseases, changes in IgG 
glycosylation reflect the increased inflammation which 
usually accompanies these conditions [12]. The impact of 
IgG glycosylation on its ability to modulate inflammation 
has been extensively studied as a potential biomarker for 
disease prognosis and treatment response, as well as for 
monoclonal antibody development [26, 27]. 
 
The composition of IgG N-glycome is also strongly 
influenced by sex hormones, age, and lifestyle such as 
smoking and body mass index [12, 28, 29]. Functional 
relevance of the impact of sex hormones on IgG 
glycosylation is notable through pregnancy-related 
remission in rheumatoid arthritis patients. Namely, the 
third trimester of pregnancy is characterized by anti-
inflammatory IgG glycan profile and disease remission, 
due to high estradiol levels, while in post-partum period 
hormone levels decrease and IgG glycan profile 
changes back to pro-inflammatory, with a high risk of 
disease resurgence [30]. Since estrogen levels change 
during lifetime in women, sex-specific changes in 
glycosylation patterns can be observed, especially in 
levels of IgG galactosylation [31]. 
 
Ageing is a process of damage aggregation in an 
organism, characterized by increase of inflammation and 
decline in health, leading to disease and death [32]. It is 
influenced by both genetic factors and environment. 
Complex changes in IgG N-glycome have been reported 
during ageing, with the most extensive changes being 
related to the level of galactosylation. Namely, 
digalactosylated structures decrease, while 
agalactosylation increases with age [28]. Level of 
bisecting GlcNAc also increases with age, while changes 
in level of sialylation and core fucosylation displayed 
inconsistent trends in different studies [28]. IgG glycans 
have been shown to be more reliable estimators of age 
compared to other biomarkers, explaining up to 64% of 
the variation in chronological age [12]. Mechanisms 
underlying age-specific changes in galactosylation levels 
remain mostly unknown. Since ageing is an 
inflammation-related process, it has been proposed that 
chronic low-grade inflammation in older individuals 
decreases IgG galactosylation. On the other hand, 
undergalactosylated IgG exerts pro-inflammatory 
potential and by this positive feedback loop contributes to 
biological ageing [33, 34]. 
 
Despite the fact that structural and functional aspects of 
IgG glycosylation are intensively studied and associated 
with predisposition and course of different diseases, little 
is known about the regulation of IgG glycosylation or 
mechanisms that lead to extensive changes in glycome 
composition after environmental challenge [12, 35, 36]. 
Therefore, the focus of this study was to analyze and 
compare IgG N-glycosylation patterns in various 
populations and communities across the world, marked by 
their different genetic background and socioeconomic 
factors. 
 
RESULTS 
 
In this study, we analyzed total IgG glycans and subclass 
specific Fc glycopeptides from various countries and 
communities. In both cases we observed significant 
changes in IgG glycosylation associated with age, sex 
and country of residence, where age and country of 
residence were able to explain a significant portion of 
glycosylation variability. IgG glycans also strongly 
correlated with the development level of a country and 
with specific development indicators as well. 
 
Total IgG glycans change with chronological age and 
sex 
 
In the initial analysis, samples originating from 10,482 
individuals and 5 different general populations 
(Supplementary Table 1) were analyzed. Fluorescently 
labelled N-glycans released from IgG were 
chromatographically profiled and separated into 24 
chromatographic peaks (Supplementary Figure 1, 
Supplementary Table 2). This approach enables 
analysis of total IgG N-glycans (i.e., from both Fab 
and Fc parts of the molecule). Additionally, derived 
glycan traits (agalactosylation, monogalactosylation, 
digalactosylation, core fucosylation, sialylation and 
presence of bisecting GlcNAc) were calculated, based 
on the initial 24 glycan measures (calculation of 
derived glycan traits can be found in Supplementary 
Table 3) [23]. In general, agalactosylation levels 
showed the highest dispersion of all tested glycan 
traits (Q1=20%, Q3=32%; Supplementary Table 4), 
which coincides with the previous studies. 
 
It is known that the chronological age of a subject affects 
IgG glycosylation [28]. Age-related changes were 
observed in the levels of various IgG glycan traits in all 
studied populations. Agalactosylated species and glycans 
containing bisecting GlcNAc increased with the 
chronological age of the participant. The opposite trend 
was observed in the levels of digalactosylated and 
sialylated glycans, which were decreasing with 
chronological age. On the other hand, core fucosylation 
and monogalactosylation levels did not change 
consistently with age. Furthermore, age-related changes 
in glycosylation displayed sex-specific patterns. Namely, 
female participants displayed characteristic increase in 
agalactosylated glycan species at the age of 50, which 
was not observed in the male population (Figure 1A). 
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Figure 1. Total IgG glycan levels in five different populations. Relationship between age and derived glycan trait (A). Plots describe 
associations between each of the five glycan traits and chronological age of participant. Blue and red curves represent fitted linear regression 
models. The shaded region is the 95 % confidence interval on the fitted values. Differences in total IgG glycosylation between participants 
from five different populations (B). Each box represents interquartile range (25th to 75th percentiles). Lines inside the boxes represent the 
median values, while lines outside the boxes represent the 10th and 90th percentiles. Dots indicate outliers. 
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Age and country of residence explain most of 
variability in IgG glycosylation 
 
Although total IgG N-glycans showed similar age-
related changes within each of the studied cohorts, 
every population displayed particular glycan patterns. 
Again, the most pronounced differences between 
populations were observed in the levels of 
agalactosylated glycans, which increased with a 
median age of the analyzed population (Figure 1B). 
This glycan trait had the lowest median value in young 
Chinese cohort (20%), while the highest value was 
observed in Estonian cohort (36%), which was the 
oldest. Besides agalactosylation, pronounced 
differences between populations were also observed in 
the levels of digalactosylated and sialylated glycans 
(Supplementary Table 4). A linear mixed model was 
used to further elucidate changes in IgG glycan traits 
in different populations. Relations of age, country of 
residence and sex with the total IgG glycans were 
evaluated. Chronological age was able to moderately 
explain variability of total IgG glycan traits – for 
digalactosylation and agalactosylation it explained up 
to 31% of their variability. Contrary to age, 
participant’s country of residence was able to explain 
larger portion of variability of core fucose levels 
(P<6×10-350, n=5), with 57 % of the variability in this 
glycan trait explained. It was also able to account for 
the portion of monogalactosylation and sialylation 
variability. On the other hand, sex was able to explain 
less than 1% of the variability of any tested glycan 
trait (Supplementary Table 5). 
 
Fragment crystallizable glycan patterns of 27 
different populations 
 
To validate observed diversity and unambiguously 
determine IgG N-glycosylation patterns in different 
populations (Supplementary Table 6), while eliminating 
potential batch effects, we compared glycan features 
derived from IgG subclass-specific Fc glycopeptides 
from 2,579 individuals (Supplementary Table 7, 
Supplementary Figure 2). This part of the study 
included 27 populations collected in 14 different 
countries. Subclass-specific glycopeptides were 
chromatographically separated and accurate masses 
were measured for each glycoform. Structures of IgG 
glycopeptides were confirmed using tandem mass 
spectrometry (MS/MS) analysis of a pooled sample 
(Supplementary Figures 3–5). Calculated IgG Fc N-
glycan derived traits displayed considerable dispersion 
between analyzed populations (Figure 2). The Fc N-
glycome composition is known to differ from the total 
IgG N-glycome, as a result of Fab N-glycome 
contribution to the total IgG glycome [37]. Again, the 
most prominent variation appeared to be in the level of 
galactosylation related traits, especially agalactosylation 
(Supplementary Tables 7–9). On the other hand, 
expected decrease in digalactosylation levels with the 
population’s age was not observed. On the contrary, 
some populations appeared to have lower than expected 
monogalactosylation and digalactosylation levels for the 
given chronological age. Population from Papua New 
Guinea, as the youngest one, surprisingly had the 
highest median level of agalactosylation (45 %), while 
the subjects from England exhibited the lowest levels of 
this glycan trait (28 %) on IgG1 subclass. The opposite 
effect was observed for monogalactosylation levels - the 
subjects from Papua New Guinea had the lowest median 
value of this glycan trait, while the highest levels were 
observed for the participants from England. In a similar 
manner, participants from countries such as Germany 
and Italy had higher monogalactosylation levels 
(comparable to subjects from England) than the ones 
from countries such as Uganda (similar to subjects from 
Papua New Guinea; Supplementary Table 7).  
 
In the case of IgG2 and IgG4 subclasses, 
galactosylation related glycan traits displayed similar 
variation as for IgG1 subclass, although the observed 
glycosylation patterns appeared to be somewhat 
subclass-specific, especially in case of IgG4, which is 
the least abundant subclass in the human plasma 
(Supplementary Tables 8 and 9). 
 
Age and country of residence can explain IgG Fc 
glycosylation variability 
 
To determine the relationship between IgG Fc glycan 
traits and sex, chronological age and country of 
residence, linear mixed model was used. The same as in 
the case of total IgG glycans, chronological age was 
able to explain a considerable portion of 
agalactosylation and digalactosylation variability. It was 
able to explain 28 % of IgG2 agalactosylation 
variability compared to 22 % for IgG1 subclass. 
Country of residence was able to explain the highest 
portion of IgG Fc monogalactosylation variability 
(Table 1). Namely, 38 % of IgG1 Fc 
monogalactosylation variability could be explained with 
the subject’s country of residence. Here as well, sex was 
able to explain up to 1% of the IgG Fc glycan 
variability. Glycan patterns similar to IgG1 subclass 
were observed for IgG2 and IgG4. 
 
IgG Fc galactosylation features correlate with the 
development level of a country 
 
In order to resolve relations between country of 
residence and studied IgG Fc glycan traits, we analyzed 
correlations between 45 development indicators and 5 
derived glycan traits of each analyzed IgG subclass 
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(Supplementary Table 10). Development indicators are 
standardized statistical measures which quantify the 
quality of life across nations and communities 
(Supplementary Tables 11 and 12). Our analysis 
resulted with 44 statistically significant correlations of 
IgG Fc monogalactosylation, digalactosylation and 
agalactosylation with 23 different development 
indicators. The strongest correlation was observed 
between IgG1 monogalactosylation and Millennium 
Development Goals (MDG), Human Development 
Index (HDI) and stunting. On the other hand, we did 
not observe any significant correlations between any of 
the development indicators and sialylation or the 
incidence of bisecting GlcNAc on any of the IgG 
subclasses. 
 
We found a positive correlation between United Nation’s 
Human development index (HDI) and IgG1 Fc 
monogalactosylation, while HDI negatively correlated 
with IgG1 agalactosylation (Figure 3). These findings 
were replicated for IgG2 subclass as well, where HDI 
positively correlated with monogalactosylation levels. 
Therefore, participants from developing countries appear 
to have lower levels of IgG Fc monogalactosylation and 
digalactosylation when compared to their counterparts 
from developed countries. 
 
 
 
Figure 2. Levels of derived IgG1 Fc glycan traits across 27 different populations collected worldwide. Each box represents 
interquartile range (25th to 75th percentiles) with median values drawn as the middle line. Whiskers outside the boxes represent the 10th and 
90th percentiles, while dots indicate outliers. 
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Table 1. Proportion of glycan feature variability in 14 countries explained by linear mixed model, with age and sex 
defined as fixed effects and country of residence as a random effect.  
IgG 
subclass Glycan feature  
Percentage of glycan 
trait variability 
explained by country 
of residence (%) 
Percentage of glycan 
trait variability 
explained by age (%) 
Percentage of 
glycan trait 
variability explained 
by sex (%) 
Country of 
residence P 
value 
 Agalactosylation 21.4 18.3 0.9 1.03 × 10-111 
 Monogalactosylation 38.0 2.6 0.1 7.69 × 10-193 
IgG1 Digalactosylation 18.6 21.7 1.1 3.51 × 10-98 
 Sialylation 10.8 13.2 0.6 1.27 × 10-54 
 Bisecting GlcNAc 18.6 17.5 0.0 9.28 × 10-110 
 Agalactosylation 12.8 23.9 0.9 7.18 × 10-62 
 Monogalactosylation 20.8 7.6 0.1 3.34 × 10-94 
IgG2 Digalactosylation 10.4 27.5 1.1 2.70 × 10-54 
 Sialylation 6.5 18.2 0.5 1.22 × 10-27 
 Bisecting GlcNAc 12.4 11.9 0.1 3.66 × 10-64 
 Agalactosylation 20.5 13.7 0.4 1.32 × 10-93 
 Monogalactosylation 20.8 2.6 0.1 1.30 × 10-78 
IgG4 Digalactosylation 18.2 14.1 0.8 1.28 × 10-86 
 Sialylation 15.4 9.7 0.5 6.44 × 10-75 
 Bisecting GlcNAc 7.6 15.7 0.6 2.01 × 10-37 
Displayed values represent percentage (%) of glycan trait variability explained by country, age and sex. 
 
 
 
Figure 3. Relationship between IgG1 Fc galactosylation levels with development indices. Relationship between IgG1 Fc 
monogalactosylation (A) and relationship between IgG1 Fc agalactosylation (B) with United Nations’ development indices for a specific 
country of residence. HDI = Human Development Index; SDG = health-related Sustainable Development Goals index; MDG = health-related 
Millennium Development Goals index. 
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IgG Fc monogalactosylation correlates with 
population’s health status 
 
To determine the relationship between health quality 
and IgG glycans, correlations between the two were 
calculated. Population’s health quality was expressed 
through general health indices (HDI, SDG, MDG) and 
specific health indicators such as stunting, mortality and 
life expectancy. Countries with lower development 
level, in general, had also lower health-related 
indicators (Supplementary Table 13). The majority of 
health-related indicators appeared to be correlated with 
IgG Fc monogalactosylation (Supplementary Table 10). 
Millennium Development Goals (MDG) index, which 
describes health-related indicators in MDG system, was 
positively correlated with IgG1 and IgG2 
monogalactosylation (r=0.97, P=7.44×10-6 and r=0.86, 
P=4.59×10-2 respectively) and negatively correlated 
with IgG1 agalactosylation (r=-0.90, P=8.16×10-3). In a 
similar fashion, a positive correlation was observed 
between IgG1 monogalactosylation and Sustainable 
Development Goals (SDG) index, non-MDG index 
(health-related SDG indicators not included in MDG) 
and Health index, which, like MDG index, display 
overall health quality of a specific country. SDG index 
was also negatively correlated with IgG1 
agalactosylation (Supplementary Table 10, Figure 3). 
 
Besides general health-related indices, specific health-
related indicators also correlated with IgG Fc 
agalactosylation, monogalactosylation and 
digalactosylation. Among all studied specific indicators, 
the decline in stunted growth prevalence demonstrated 
the strongest positive correlation with IgG1 
monogalactosylation (r=0.97, P=1.16×10-5; n=14). 
Among other studied indicators, universal health 
coverage and the decrease in occupational risk burden 
displayed substantial correlations with IgG Fc 
agalactosylation and monogalactosylation levels. Life 
expectancy is also one of the most important indicators, 
used to describe life quality. Both female and male life 
expectancies were correlated with IgG Fc 
monogalactosylation. Individual’s exposure to various 
antigens was presented through indicators such as 
hygiene, water availability, WaSH mortality and 
sanitation, which also showed significant correlations 
with IgG Fc galactosylation levels. Of the various 
infectious diseases, only hepatitis B showed a 
significant correlation with IgG Fc monogalactosylation 
(Supplementary Table 10). 
 
Moreover, digalactosylation of IgG1 demonstrated five 
positive correlations with health-related development 
indicators, where skilled birth attendance and again, 
stunted growth, had the strongest associations with this 
glycan trait (Supplementary Table 10). 
Although IgG1 Fc glycans showed the strongest 
correlation with the health-related indicators, significant 
correlations between IgG1 Fc galactosylation related 
glycan features and the socioeconomic indicators, such 
as education and economic development, have also been 
identified. Education index was significantly correlated 
with both Fc monogalactosylation (r=0.94, P=5.14×10-4,  
n=14) and agalactosylation (r=-0.90, P=1.02×10-2, 
n=14), while Gross Domestic Product (GDP) was 
significantly correlated only with monogalactosylation 
(r=0.89, P=1.46×10-2, n=14; Supplementary Table 10). 
Correlation analysis between development indicators 
used in this study displayed high dependencies between 
used variables (Supplementary Table 14). 
 
DISCUSSION 
 
This is the largest study to date that has analyzed IgG 
glycosylation in various populations, encompassing 
10,482 of total IgG N-glycomes originating from 5 
different populations and 2,579 Fc IgG glycopeptide 
profiles of subjects from 27 populations. As suggested 
by previously published data, we observed considerable 
variation of IgG N-glycan profiles between individuals 
within the same population, as well as between different 
populations [23, 38]. 
 
Within five populations, where glycans from the whole 
IgG molecule were analyzed, we observed changes in 
glycan patterns depending on age and sex. Sex-specific 
changes are thought to be caused by differences in 
hormone composition between sexes, especially 
estrogen that can vary due to pregnancy, menopause or 
hormonal therapy [23]. This is clearly visible in female 
N- glycan profiles, where around the age of 50, a 
decrease of galactosylated IgG glycoforms can be 
detected. This decrease in galactosylation is associated 
with alterations and finally decrease of estrogen levels 
during menopausal transition and post-menopause [39]. 
Despite the fact that the exact mechanism remains 
unknown, it has been proposed that high levels of 
estrogen and progesterone decrease inflammation 
through reduced production of inflammatory cytokines 
and induction of helper T lymphocytes [40]. 
 
IgG glycosylation is also known to change with 
chronological and biological age of an individual [28]. 
We observed an expected decrease in levels of 
digalactosylation and increase in bisecting GlcNAc 
levels with the age of participant. Age-related decline in 
IgG galactosylation is associated with the increase in 
systemic low-grade inflammation which can be observed 
in older people [28, 41]. This increase in inflammation is 
usually explained by higher levels of pro-inflammatory 
cytokines, such as tumor necrosis factor-α and 
interleukin-6, found in aged individuals [42]. In 
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accordance, decreased galactosylation also enhances the 
pro-inflammatory potential of IgG. The decrease in IgG 
galactosylation has also been observed in premature 
ageing syndromes, which are also accompanied by 
inflammation, as in numerous inflammatory and 
autoimmune diseases, such as inflammatory bowel 
disease (IBD), rheumatoid arthritis and systemic lupus 
erythematosus [26, 36, 41, 43]. Although exact 
mechanisms underlying age-related changes in IgG 
glycan profile remain unknown, there are several 
proposed pathways which could explain them. Possible 
mechanisms include various expression or activity of 
enzymes involved in glycosylation processes in B-cells 
and clonal selection of B-cells with specific 
glycosylation patterns [44, 45]. Therefore, through 
modulation of inflammation, IgG galactosylation, or 
more precisely agalactosylation, is proposed to 
contribute to a process of biological ageing [46]. 
 
We have demonstrated differences in glycan profiles 
between analyzed populations with both analytical 
approaches – with total IgG N-glycans and Fc 
glycopeptides, which suggests population-specificity of 
IgG glycosylation. The highest differences in Fc 
glycopeptides between analyzed countries were 
observed in their galactosylation levels. Furthermore, 
we found that the indices describing country’s 
development level, expected lifespan and numerous 
health related indicators were positively correlated with 
IgG galactosylation levels, especially with 
monogalactosylation. We have also observed significant 
correlations between IgG Fc galactosylation-related 
glycan traits and the socioeconomic indicators. 
Economy and education quality are tightly connected 
with the development level and quality of the healthcare 
system [47]. As a matter of fact, all analyzed 
development indicators appeared to be highly co-
dependent, making it impossible to pinpoint specific 
indicator associated to a distinct galactosylation change 
(Supplementary Table 14). It is known that besides 
genetics, environment also plays a crucial role in the 
regulation of IgG glycosylation [25, 36]. Pathogens, 
stress, certain medications and nutrition are the most 
probable players orchestrating non-genomic component 
of IgG glycosylation [24, 48, 49]. Low galactosylation 
levels suggest higher IgG inflammatory potential in 
some of the analyzed populations. Therefore, it would 
be interesting to check if participants from populations 
with lower IgG galactosylation had an underlying 
inflammatory condition at the time of sampling or if 
measured IgG galactosylation level represents a 
baseline for the studied population. However, clinical 
data on inflammation markers were not available for 
this study, warranting further research with improved 
study design to resolve the aforementioned 
predicament. Nevertheless, it was reassuring to see that 
our results replicate previous findings in a recent study 
on 773 children from Gabon, Ghana, Ecuador, the 
Netherlands and Germany, where the increase in 
agalactosylated species was observed in individuals 
from Gabon, Ghana and Ecuador, compared to 
participants from the Netherlands and Germany. The 
study suggested that higher exposures to antigens in 
developing countries may drive pro-inflammatory IgG 
glycan profile and activate immune system against 
pathogens [38]. Significantly lower IgG Fc 
galactosylation levels were also observed in two 
African populations in comparison to US participants, 
suggesting associations with inflammatory 
glycosylation as well [50].  
 
As already mentioned, IgG glycosylation is responsive 
to various environmental factors, including nutrition 
and use of certain medications. For instance, dietary 
habits vary substantially between countries, especially if 
we compare countries on different continents. Various 
diets in different regions could also be a possible source 
of variation in glycan profiles. It was demonstrated in 
mouse models that high fat diet alters IgG 
glycosylation, consequently activating signaling 
pathways that induce insulin resistance and 
hypertension, directly impacting cardiometabolic health 
[51, 52]. Additionally, use of certain medications, such 
as immune modifying analgesics, causes changes in 
immune activation [53]. The use and availability of 
these drugs differs significantly between the countries 
and could potentially represent a confounding factor to 
the observed changes in IgG galactosylation levels 
between the studied populations. However, clinical data 
on the use of immunomodulating drugs at the time of 
sampling were not available, disabling further 
investigation of this matter. 
 
Our study shows differences in glycan profiles 
between analyzed cohorts and intriguing associations 
with various country development indicators, but has 
several limitations. Although most of our cohorts are 
representative of their base populations, we cannot 
exclude the possible existence of sampling bias in 
some cohorts, due to inconsistencies in inclusion 
criteria and lack of information on sampling methods. 
Example of this limitation is a cohort of Thailand sex-
workers, where participants with a high risk of HIV 
infection were enrolled. Although all included 
participants were HIV negative, the group included sex 
workers and hepatitis positive individuals and 
therefore in not a true representative of Thailand’s 
base population. We did not observe substantial 
differences in monogalactosylation levels for this 
cohort when compared to other cohorts in region 
(China Han). However, further studies are needed to 
properly check if there are differences in glycan 
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profiles between a base population and a population 
with high risk of HIV infections in Thailand. 
Additionally, although European countries are well 
represented, the rest of the world is still 
underrepresented. For example, Uganda is the only 
population from African continent and this 
representation of genetical, socio-economical, cultural 
and behavioral differences cannot be generalized to the 
whole continent.  
 
Additional studies with adequate number of 
representative participants from each of the included 
base populations are needed to obtain baseline 
populational IgG glycosylation profiles. To tackle the 
source of variation in glycan profiles in various 
populations, information on participant’s health status, 
detailed medical history and biochemical markers 
would have to be collated. Unfortunately, sensibility of 
existing analytical methods to experimental variation 
and cofounding effect of age on glycan profile limits the 
availability of adequate sample sets for such analysis. 
Nevertheless, possible skewness of cohort participants 
in some populations should not affect and invalidate 
presented results and conclusions. 
 
In summary, this observational cohort study revealed 
that immunoglobulin G glycosylation patterns vary 
within and between different populations. In addition 
to corroborating the previous findings on age- and sex-
related IgG glycosylation changes, we also observed 
associations related to participants' country of 
residence. Moreover, certain IgG patterns could be 
associated with pronounced inflammatory potential in 
some populations. We also obtained intriguing 
correlations between IgG galactosylation and various 
development indicators describing populational  
health, education and income, leaving cause of these 
changes as an open question to be answered by further 
studies. 
 
MATERIALS AND METHODS 
 
Study participants 
 
Total IgG glycome analysis was based on 10,482 
human participants from China [36, 54], Croatia [55], 
Estonia and two cohorts from the United Kingdom 
(population of Scotland from Orkney Islands [23] and 
England from the TwinsUK cohort [56]; Supplementary 
Table 1). 
 
Subclass specific analysis of IgG Fc glycosylation 
included 2,579 individuals. Volunteers originated from 
14 different countries and 25 different ethnic groups 
(Supplementary Table 6). For Kazak and English 
cohorts, we had two populations obtained from different 
medical centers. In general, inclusion criteria required 
participants not to have any physiological or 
pathological conditions that are known to affect IgG 
glycosylation profile. Detailed descriptions of analyzed 
populations are below: 
 
Trinidad and Tobago 
 
Controls from the Latin American Genoma de Lupus 
Eritematoso Sistemico Network (GENLES) study were 
selected for analysis. Controls were selected from the 
same underlying population as the SLE cases of 
African/European genetic admixture. For each SLE 
case, two controls, matched for sex and for 20-year age 
group, were randomly chosen from the neighborhood 
[36]. Sampling may underrepresent predominantly 
Chinese and Indian populations, but 5-way admixture in 
samples (African, European, Indian, Chinese, Native 
American) reflects the diverse ancestry. 
 
Han Chinese; Kazak, Kyrgyz and Uyghur minorities 
 
Han Chinese samples were collected in Beijing 
(northern China) and Tangshan (eastern China) to 
represent the majority of Han Chinese.  
 
Kazak, Kyrgyz and Uyghur participants were recruited 
from Xinjiang Autonomous Region to represent the 
Chinese minority ethnics. Kyrgyz samples originated 
from Halajun Town, Atushi City, Kizilsu Kirghiz 
Autonomous Prefecture. Kazak samples originated from 
Qapqal county, Ili Kazak Autonomous Prefecture. 
Uyghur samples originated from Minfeng County, 
Hotan Prefecture. All the participants had to meet the 
following inclusion criteria: signed informed consents 
before participation, aged more than 18 years,  
self-reported Kyrgyz / Kazakh/ Uyghur ethnicity 
without intermarriage history with other ethnic groups 
within at least the past three generations and no 
documented clinical diagnosis of specific diseases. 
Individuals who met the diagnostic criteria for the 
specific cardiovascular, respiratory, genitourinary, 
gastrointestinal or hematological disease were excluded 
from the study [29, 34, 57, 58]. 
 
India, England and Jamaica 
 
Representatives for India, England and Jamaica were 
selected from a SABRE study. First-generation 
migrants from India and Jamaica were initially recruited 
as a population-based sample aged 40–70 years and 
randomly selected from ethnicity and sex-stratified 
primary care practitioners’ lists. Only participants with 
no coronary heart disease, stroke and diabetes were 
selected for analysis. This population has the same 
health status as the older general population in the UK. 
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Ethnicity was described by the interviewer based on 
appearance and parental origin [59]. 
 
Roma population 
 
The Croatian Roma samples used in this study were 
selected from the database collected during 
multidisciplinary anthropological and epidemiological 
community-based investigations of adult Roma 
individuals living in Croatia. The collected samples 
represent a general population of adult Roma living in 
Croatia. The subsample presented in this cohort is created 
in order to equally represent both sexes and both main 
linguistic subgroups of the Roma: Bayash (Vlax) and 
Balkan Roma. Furthermore, this sample equalizes the 
number of individuals in 10-years age groups that are 
approximately the same in men and women, and in the 
Bayash and Balkan Roma [60]. 
 
Sweden 
 
Participants were blood donors which were recruited 
within the Örebro region (the primary catchment area of 
the Örebro University Hospital). In addition to the 
normal requirements for blood donors, i.e. age 18–60 
years, not being diagnosed with any transmittable 
disease or chronic disease that may impact on the 
composition of the blood, not having done any 
tattoo/piercing within the last 6 months, not undergone 
surgery within the last 1-6 months (depending on type 
of surgery) and not having any ongoing infections. Any 
chronic gastrointestinal symptoms were used as an 
exclusion criterion. The age profile of the inhabitants in 
the region is like that of Sweden. 
 
Thailand  
 
Participants were recruited from bars, clubs, and other 
locations associated with transactional sex. Men and 
women, 18 to 50 years of age, who were at high risk 
for HIV-1 infection were identified with the use of an 
audio computer-assisted self-interview. To be eligible 
for study entry, participants had to meet at least one of 
the following four criteria within the previous 3 
months: had exchanged goods for sex, had unprotected 
sex with a known HIV-positive partner, had 
unprotected sex with three or more partners, and had 
symptoms of a sexually transmitted infection. 
Participants who were HIV -negative were analyzed in 
this study [61]. 
 
Uganda 
 
Residents of Kayunga District, Uganda aged 15 to 49 
years were enrolled. Contact information was obtained, a 
blood sample collected, and a questionnaire administered. 
Participants also provided a medical history and received 
a physical examination that included observations for 
weight, temperature, blood pressure, pulse and presence 
of lymphadenopathy. A blood sample was then obtained 
for HIV-1 testing. Samples from HIV-negative 
participants were included in this study [62]. 
 
Evenks 
 
Evenki samples were studied for genetic markers and 
biochemical traits. They are representatives of the 
Evenki populations of Siberia. The people studied were 
healthy as that population is and have minimum modern 
medical care. 
 
Yakuts 
 
Yakut samples were part of genetic markers study of 
horse ranchers of Mongolian origin. They are a more 
recent migrant population to Siberia. 
 
Papua New Guinea 
 
The Watut population, which is a representative of the 
transitional Highland populations of New Guinea, was a 
part of a Tropical Splenomegaly syndrome study. 
Analyzed samples in this study were controls that did 
not have the disease. 
 
Slavs, Kazakhs, Tatars and Yakuts  
 
Slavs, Kazakhs, Tatars and Yakuts were collected as 
part of local projects for population genetic studies. The 
goal was to collect conditionally healthy population 
controls. 
 
Slavs were blood donors who have clinically shown no 
infectious and chronic diseases selected for Slavic 
ethnic origin. Ethnicity was evaluated in the interview 
process, as well as visually where people with Asian 
features were excluded. 
 
Kazakhs were collected in National Center for 
Biotechnology, Astana, Kazakhstan. It is a conditionally 
healthy population control group to evaluate HLA 
alleles distribution in Kazakhs. Ethnicity was evaluated 
in the interview process. 
 
Tatars were collected at Kazan Federal University, 
Kazan, Republic of Tatarstan for forensic purposes. 
Blood donors have clinically shown no infectious and 
chronic diseases. Ethnicity was evaluated in the 
interview process. 
 
Yakut samples were collected in the Institute of Health, 
North-Eastern Federal University, Yakutsk, Russia. 
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Samples were collected in the areas of native habitats of 
the Yakuts containing a pure ethnic group. 
 
Orkney and Shetland islanders 
 
Participants were selected among controls for patients 
with multiple sclerosis (MS) living on the islands or in 
the Grampian or Highland regions of mainland 
Scotland were identified by contacting general 
practices on the islands and reviewing MS databases 
held in secondary care in Aberdeen, Inverness, Orkney 
and Shetland. Recruitment of cases to the study was 
conducted through letters forwarded by general 
practitioners inviting those of Orcadian or Shetlandic 
descent to participate. [63]. 
 
TwinsUK population 
 
The UK's largest registry of adult twins, or TwinsUK 
Registry, encompasses about 12,000 volunteer twins 
from all over the United Kingdom. More than 70 % of 
the registered twins have filled at least one detailed 
health questionnaire and about half of them have 
undergone a baseline comprehensive assessment and 
two follow-up clinical evaluations [56]. 
 
Croatia 
 
The participants originated from the City of Split (2012-
2013). The participants were recruited in the study 
following general practitioner’s advice, newspaper and 
radio announcements, or distribution of posters and 
leaflets. In order to participate, the participants had to be 
of age (18 or more years) and had to sign the informed 
consent prior to the enrolment [64]. 
 
Germany 
 
Samples representing Germany were collected in a 
genetic epidemiological research, based on the KORA 
platform (Cooperative Health Research in the Region of 
Augsburg). Biosamples and phenotypic characteristics, 
as well as environmental parameters of 18,000 adults 
from Augsburg and the surrounding counties are 
available [49]. 
 
Kosovo 
 
Samples were collected from Kosovars of Albanian 
ethnicity in the area of Podujevo city and neighboring 
villages. 
 
Italy 
 
Used samples were a subgroup of 427 controls for IBD 
glycome project that did not have the disease. 
Participants were enrolled at Careggi University 
Hospital in Florence, Italy [26]. 
 
Turkey 
 
Samples of healthy participants were collected at Koc 
University, Istanbul, Turkey. 
 
Samples were randomized across 96-well plates (31 in 
total), with five technical replicates of a standard sample 
and one blank, serving as a negative control. The 
development level of a country was assessed using three 
development indices: health-related Sustainable 
Development Goal index (SDG) [65], health-related 
Millennium Development Goals index (MDG) and 
United Nation Human Development Index (HDI) which 
is a summary measure of the development level of a 
certain country [65, 66] HDI represents three dimensions 
of life: economy, education and health quality. Specific 
aspects of human life were assessed using other 
development indicators (Supplementary Table 10). 
Blocking was performed by equally distributing subjects 
of the same sex and similar age from all the cohorts 
across used plates. Plasma samples used as standards 
were obtained from Croatian National Institute of 
Transfusion Medicine. The study was performed in 
compliance with the Helsinki declaration and all 
participants gave written informed consent. Ethical 
approvals were obtained by relevant ethics committees. 
 
Immunoglobulin G isolation 
 
For all samples, the initial material for IgG isolation 
was human blood plasma. Protein G affinity 
chromatography was used to isolate immunoglobulin 
G from plasma as described previously [23]. In short, 
the maximum volume of 100 μL of human peripheral 
blood plasma or serum was diluted with 1X phosphate 
buffer saline (PBS) and loaded onto protein G 
monolithic plate (BIA Separations, Ajovščina, 
Slovenia). Samples were washed three times with 1X 
PBS and IgG was eluted using 0.1M formic acid 
(Merck, Darmstadt, Germany) followed by immediate 
neutralization with 1M ammonium bicarbonate (Acros 
Organics, Pittsburgh, PA). 
 
Immunoglobulin G trypsin digestion and 
purification 
 
Subclass specific analysis of IgG Fc glycosylation 
included 2,579 in dividuals from 14 different  
countries and 25 different ethnic groups 
(Supplementary Table 6). We studied glycopeptides 
from three IgG sublessees; IgG1, IgG2 and IgG4 and 
each subclass was studied for various glycan features 
(Supplementary Tables 15, 16). 
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IgG glycopeptides were obtained and purified as 
described before [49]. Approximately 15 μg of isolated 
IgG was treated with 0.1 μg of sequencing grade trypsin 
(Promega, Fitchburg, WI) and incubated overnight at 37 
°C. The reaction was stopped by dilution with 0.1 % 
trifluoroacetic acid (TFA; Sigma-Aldrich, St. Louis, 
MI). Glycopeptides were purified using a solid-phase 
extraction on Chromabond C-18 sorbent (Macherey-
Nagel, Düren, Germany). Samples were loaded onto 
beads in 0.1 % TFA and washed three times using the 
same solvent. Glycopeptides were eluted from the phase 
with 20 % LC-MS grade acetonitrile (ACN; Honeywell, 
Morris Plains, NJ). Eluted glycopeptides were vacuum-
dried and reconstituted in 20 μL of ultrapure water prior 
to LC-MS analysis. All glycan analyses were performed 
at Genos laboratory. 
 
Release and labelling of the total IgG N-glycans 
 
Total IgG glycome was analyzed in participants from 
China [36, 54], Croatia [55], Estonia, Orkney Islands 
[23] and the TwinsUK cohort [56] (Supplementary 
Table 1). Glycan release and labelling of Croatian 
samples were performed as previously described [28]. 
Briefly, IgG was incorporated into sodium dodecyl 
sulphate polyacrylamide gel and glycans were released 
from protein using an overnight incubation with PNGase 
F (ProZyme, Hayward, CA). Released glycans were 
labelled with 2-aminobenzamide (2-AB; Sigma-Aldrich) 
and purified on Whatman 3 mm chromatography paper. 
For cohorts from Scotland, England, China and Estonia, 
glycans were released as previously described [28, 48]. 
Briefly, IgG was denatured using 1.33 % (w/v) sodium 
dodecyl sulphate (Invitrogen, Carlsbad, CA) and 
samples were incubated at 65 °C for 10 minutes. 
Subsequently, 4 % (v/v) Igepal CA-630 (Sigma–
Aldrich) and 1.25 mU of PNGase F (ProZyme) were 
added to each sample and incubated overnight at 37 °C. 
For glycan labelling, 48 mg/mL of 2-AB in dimethyl 
sulfoxide (Sigma–Aldrich) and glacial acetic acid 
(Merck) (v/v 85:15) was mixed with reducing agent 
(106.96 mg/mL of 2-picoline borane (Sigma–Aldrich) in 
dimethyl sulfoxide). Labelling mixture was added to 
samples, followed by 2-hour incubation at 65 °C. 
 
After incubation, Estonian and Chinese samples were 
brought to 96 % ACN (J.T. Baker, Phillipsburg, NJ) and 
applied to each well of a 0.2 μm GHP filter plate (Pall 
Corporation, Ann Arbor, MI). Samples were 
subsequently washed five times using acetonitrile/water 
(96:4, v/v). Glycans were eluted with water and stored 
at -20 °C until usage. Samples from England and 
Scotland were purified using a solid-phase extraction on 
200 μL of 0.1 g/L microcrystalline cellulose suspension 
(Merck) in a 0.45 μm GHP filter plate (Pall 
Corporation). Deglycosylation reaction was diluted four 
times with ACN loaded to cellulose. Samples were 
washed three times with 80 % ACN and eluted with 
ultrapure water.  
 
HILIC-UPLC analysis of fluorescently labelled N-
glycans 
 
Fluorescently labelled N-glycans were separated by 
hydrophilic interaction liquid chromatography (HILIC) 
on a Waters Acquity UPLC H-class instrument (Waters, 
Milford, MA) equipped with FLR fluorescence detector 
set to 330 nm for excitation and 420 nm for emission 
wavelength. Separation was achieved on a Waters 
bridged ethylene hybrid (BEH) Glycan chromatography 
column, 100 × 2.1 mm i.d., 1.7 μm BEH particles with 
100 mM ammonium formate (pH 4.4) as a solvent A 
and ACN as a solvent B. Separation method used linear 
gradient from 75 % to 62 % solvent B (v/v) at a flow 
rate of 0.4 mL/min in a 25-minute analytical run. 
Column temperature was maintained at 60 °C. Obtained 
chromatograms were manually separated into 24 peaks 
using Empower 3 software, from which, using the total 
area normalization, relative abundances of 24 directly 
measured glycan traits were obtained (Supplementary 
Table 2). In-depth characterization of each of 24 
chromatographic peaks was performed as previously 
described [23]. The most abundant glycan structure in 
each peak was chosen to represent that glycan peak. An 
example of chromatogram integration with the most 
abundant glycan structures in each peak of IgG glycome 
is shown in Supplementary Figure 1. 
 
LC-MS analysis of IgG Fc glycopeptides 
 
Trypsin-digested, subclass-specific glycopeptides were 
separated and measured on nanoAcquity 
chromatographic system (Waters, Milford, MA) 
coupled to Compact mass spectrometer (Bruker, 
Bremen, Germany), equipped with Apollo II source as 
described previously with minor changes [67]. 
Samples (9 μL) were loaded onto PepMap 100 C8 trap 
column (5 mm × 300 µm i.d.; Thermo Fisher 
Scientific, Waltham, MA) at a flow rate of 40 μL/min 
of solvent A (0.1 % TFA) and washed of salts and 
impurities for one minute. Subclass-specific 
glycopeptides were separated on C18 analytical 
column (150 mm × 100 µm i.d., 100 Å; Advanced 
Materials Technology, Wilmington, DE) in a gradient 
from 18 % to 25 % of solvent B (80 % ACN) in 
solvent A. Column temperature was set to 30 °C and 
flow rate was 1 µl/min. NanoAcquity was coupled to 
mass spectrometer via capillary electrophoresis 
sprayer interface (Agilent, Santa Clara, CA), which 
allows mixing of analytical flow with sheath liquid 
(50 % isopropanol, 20 % propionic acid; Honeywell, 
Morris Plains, NJ). 
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Mass spectrometer was operated in a positive ion mode, 
with capillary voltage set to 4500 V, nebulizer pressure 
set to 0.4 bar and drying gas set to 4 L/min at 180 °C. 
Spectra were recorded in a m/z range of 600 - 1800. 
Collision energy was 4 eV.  
 
IgG glycopeptides were confirmed by tandem mass 
spectrometry (MS/MS) analysis of a pool of 90 
randomly chosen samples. MS/MS analysis was 
performed on Compact instrument using CaptiveSpray 
interface. Gaseous acetonitrile was introduced into 
nitrogen flow using nanoBooster. Capillary voltage was 
set to 1500 V with nitrogen pressure set to 0.2 bar and a 
temperature of 150 °C. AutoMS/MS method was used 
with selection of three precursor ions and exclusion 
criteria after one MS/MS spectrum. Mass range was set 
from 150 m/z to 3400 m/z and spectra rate of 1 Hz. 
Transfer time was set to 100 μs and pre-pulse storage 
was 12 μs. Used separation method was the same as for 
the analyzed samples, except there was no sheathing-
liquid flow applied to the source. Fragment spectra were 
manually searched for diagnostic peptide y-ion series 
and glycopeptide fragments specific for IgG 
glycopeptides (Supplementary Figures 3–5). 
 
Obtained raw data was converted to centroid mzXML 
files using ProteoWizard version 3.0.1. software. 
Samples were internally calibrated using a defined list 
of IgG glycopeptides with highest signal-to-noise 
ratios and required isotopic patterns. After calibration, 
signals matching IgG Fc glycopeptides were extracted 
from data using 10 m/z extraction window. First four 
isotopic peaks of doubly and triply charged signals, 
belonging to the same glycopeptide species, were 
summed together, resulting in 20 glycopeptides per 
IgG subclass. Predominant allotype variant of IgG3 
tryptic peptide carrying N-glycans in Caucasian 
population has the same amino acid sequence as IgG2. 
On the other hand, in Asian and African populations 
predominant variant of the same peptide has the same 
amino acid composition as IgG4 making the separation 
of IgG3 from other subclasses impossible using given 
separation methods [68]. Therefore, IgG glycopeptides 
were separated into three chromatographic peaks 
labelled IgG1, IgG2 and IgG4. Signals of interest were 
normalized to the total area of each IgG subclass. 
 
Statistical analysis 
 
Data analysis was performed using program R, version 
3.0.1. with a ggplot2 package for creation of 
visualizations. Since obtained globally normalized 
abundances of glycan structures show the right-
skewness of their distributions, data were log-
transformed. To remove experimental and batch biases, 
all measurements were batch-corrected using ComBat R 
package. Derived glycan traits representing levels of 
galactosylation (agalactosylation, monogalactosylation 
and digalactosylation), sialylation, core fucosylation 
and incidence of bisecting GlcNAc were calculated 
from obtained data as described before [23, 49]. 
Derived glycan traits represent a portion of structurally 
similar glycan species which share common 
biosynthetic pathways. Level of IgG glycans containing 
galactose was represented by agalactosylation (no 
galactoses), monogalactosylation (one galactose) or 
digalactosylation (two galactoses attached to antenna). 
In short, total IgG derived glycan traits were calculated 
as portion of glycans (%) containing common structural 
features (e.g. number of galactoses) in a total IgG 
glycome (Supplementary Table 3). In case of subclass 
specific IgG Fc glycopeptide analysis, derived glycan 
traits were calculated as a portion of glycopeptides 
containing common structural features within a specific 
IgG subclass (Supplementary Table 16). Correlations 
between derived glycan traits are defined in 
Supplementary Tables 17 and 18. Core fucosylation was 
excluded from IgG Fc specific glycopeptide analysis 
due to low data quality of non-fucosylated species. 
 
Linear mixed model was used to analyze associations 
between glycan traits and the subject’s country of 
residence (R package “lmer”). Analysis was performed 
using linear mixed model framework since it allows to 
explicitly model the hierarchical structure of our data 
(geographical clustering of measured samples). In the 
model, sex and age were described as fixed effects, 
while the country of residence was described as a 
random effect. For each variable of interest (country of 
residence, age and sex), R2 (variance explained) was 
calculated as described in Nakagawa et al. [69]. The 
likelihood ratio test was used to determine the 
significance of country of residence variability in glycan 
trait variability. Pearson’s correlation coefficient was 
used to express relationships between country-specific 
development indicators and levels of glycan traits in 
participants from the same country. P values were 
adjusted for multiple testing using Bonferroni correction. 
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
 
Supplementary Figure 1. HILIC-UPLC chromatogram of total IgG released glycans labelled with 2-AB. Dominant structures are 
indicated above each of 24 glycan peaks (GP 1 - 24).  
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Supplementary Figure 2. Extracted ion chromatograms of IgG Fc glycopeptides. IgG1 subclass is shown in red, IgG4 in green and 
IgG2 in blue. Mass spectra containing masses that correspond to IgG1 glycopeptides and isotopic distribution of the most abundant 
glycopeptide (G1F) are shown. 
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Supplementary Figure 3. Fragment spectra of G0F glycan attached to IgG1 tryptic fragment. Glycan composition: N  
(N-acetylglucosamine), F (fucose), G (galactose) and S (N-acetylneuraminic acid) followed by a number represents number and type of 
monosaccharides attached to A2 glycan. Glycan structures are drawn in GlycoWorkbench version 2. Blue square = N-acetylglucosamine, red 
triangle = fucose, green circle = mannose, yellow circle = galactose, purple diamond = N-acetylneuraminic acid. IgG1 tryptic peptide sequence 
carrying glycan: E293EQYNSTYR301. 
 
www.aging-us.com 15244 AGING 
 
 
Supplementary Figure 4. Fragment spectra of G0F glycan attached to IgG2&3 tryptic fragment. Glycan composition: N (N-
acetylglucosamine), F (fucose), G (galactose) and S (N-acetylneuraminic acid) followed by a number represents number and type of 
monosaccharides attached to A2 glycan. Glycan structures are drawn in GlycoWorkbench version 2. Blue square = N-acetylglucosamine, red 
triangle = fucose, green circle = mannose, yellow circle = galactose, purple diamond = N-acetylneuraminic acid. IgG2&3 tryptic peptide 
sequence carrying glycan: E293EQFNSTYR301. 
 
www.aging-us.com 15245 AGING 
 
 
Supplementary Figure 5. Fragment spectra of G0F glycan attached to IgG4 tryptic fragment. Glycan composition: N  
(N-acetylglucosamine), F (fucose), G (galactose) and S (N-acetylneuraminic acid) followed by a number represents number and type of 
monosaccharides attached to A2 glycan. Glycan structures are drawn in GlycoWorkbench version 2. Blue square = N-acetylglucosamine, red 
triangle = fucose, green circle = mannose, yellow circle = galactose, purple diamond = N-acetylneuraminic acid. IgG4 tryptic peptide sequence 
carrying glycan: E293EQFNSTFR301. 
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Supplementary Tables 
 
Supplementary Table 1. Demographic characteristics of five populations used for HILIC-UPLC analysis of total IgG 
glycosylation.  
Population Abbreviation Country of residence 
Min 
age Q1 Median Mean Q3 Max age F M 
General 
population of 
China (Han) 
China China 20 43 48 47 51 68 423 201 
General 
population of 
Croatia 
Croatia Croatia 18 46 57 56 68 98 1116 689 
General 
population of 
Estonia 
Estonia Estonia 31 60 69 67 75 88 516 593 
Population of 
Orkney Islands Scotland Scotland 17 41 54 53 65 100 1236 794 
General 
population of 
England 
(TwinsUK 
cohort) 
England England 17 42 54 52 62 83 4282 342 
In table are given: abbreviation of analysed population, country of participant’s residence, age parameters (minimum, 
maximum, median, mean, 1st and 3rd quartile) and sex parameters (number of female and male participants). 
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Supplementary Table 2. Description of directly measured traits measured by HILIC-UPLC. 
Glycan peak The most abundant glycan structure1 Description of glycan trait Trait calculation
2 
GP1  The percentage of FA1 glycan in total IgG glycans GP1 / TOTAL GLYCANS* 100 
GP2  The percentage of A2 glycan in total IgG glycans GP2 / TOTAL GLYCANS* 100 
GP3  The percentage of A2B glycan in total IgG glycans GP3 / TOTAL GLYCANS* 100 
GP4  The percentage of FA2 glycan in total IgG glycans GP4 / TOTAL GLYCANS* 100 
GP5  The percentage of M5 glycan in total IgG glycans GP5 / TOTAL GLYCANS* 100 
GP6  The percentage of FA2B glycan in total IgG glycans GP6 / TOTAL GLYCANS* 100 
GP7 
 
The percentage of A2G1 glycan in total IgG 
glycans GP7 / TOTAL GLYCANS* 100 
GP8  The percentage of FA2[6]G1 glycan in total IgG glycans GP8 / TOTAL GLYCANS* 100 
GP9  The percentage of FA2[3]G1 glycan in total IgG glycans GP9 / TOTAL GLYCANS* 100 
GP10  The percentage of FA2[6]BG1 glycan in total IgG glycans GP10 / TOTAL GLYCANS* 100 
GP11  The percentage of FA2[3]BG1 glycan in total IgG glycans GP11 / TOTAL GLYCANS* 100 
GP12  The percentage of A2G2 glycan in total IgG glycans GP12 / TOTAL GLYCANS* 100 
GP13  The percentage of A2BG2 glycan in total IgG glycans GP13 / TOTAL GLYCANS* 100 
GP14  The percentage of FA2G2 glycan in total IgG glycans GP14 / TOTAL GLYCANS* 100 
GP15  The percentage of FA2BG2 glycan in total IgG glycans GP15 / TOTAL GLYCANS* 100 
GP16  The percentage of FA2G1S1 glycan in total IgG glycans GP16 / TOTAL GLYCANS* 100 
GP17  The percentage of A2G2S1 glycan in total IgG glycans GP17/ TOTAL GLYCANS* 100 
GP18  The percentage of FA2G2S1 glycan in total IgG glycans GP18 / TOTAL GLYCANS* 100 
GP19  The percentage of FA2BG2S1 glycan in total IgG glycans GP19 / TOTAL GLYCANS* 100 
GP20  Structure not determined GP20 / TOTAL GLYCANS* 100 
GP21   
The percentage of A2G2S2 glycan in total IgG 
glycans GP21 / TOTAL GLYCANS* 100 
GP22  The percentage of A2BG2S2 glycan in total IgG glycans GP22 / TOTAL GLYCANS* 100 
GP23  The percentage of FA2G2S2 glycan in total IgG glycans GP23 / TOTAL GLYCANS* 100 
GP24  The percentage of FA2BG2S2 glycan in total IgG glycans GP24 / TOTAL GLYCANS* 100 
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Supplementary Table 3. Description of derived IgG glycan traits measured by HILIC-UPLC with correlations between 
derived glycan traits. 
1Glycan structures are drawn in GlycoWorkbench version 2. blue square = N-acetylglucosamine, red triangle = fucose, green 
circle = mannose, yellow circle = galactose, purple diamond = N-acetylneuraminic acid. 
2Total glycans = sum of all 24 glycan peaks. 
  
Derived glycan trait Derived trait description Derived trait calculation 
Core fucosylation Fraction of structures containing core fucose in total IgG glycans 
GP1+GP4+GP6+GP8+GP9+GP10+GP11+GP14+GP15+GP16+GP18+GP19+GP23+
GP24 
Bisecting GlcNAc 
Fraction of structures containing 
bisecting GlcNAc in total IgG 
glycans 
GP3+GP6+GP10+GP11+GP13+GP15+GP19+GP22+GP24 
Agalactosylation Fraction of agalactosylated structures in total IgG glycans GP1+GP2+GP3+GP4+GP5+GP6 
Monogalactosylation 
Fraction of structures containing 
one galactose in total IgG 
glycans 
GP7+GP8+GP9+GP10+GP11+GP16 
Digalactosylation 
Fraction of structures containing 
two galactoses in total IgG 
glycans 
GP12+GP13+GP14+GP15+GP17+GP18+GP19+GP20+GP21+GP22+GP23+GP24 
Sialylation Fraction of structures containing sialic acid in total IgG glycans GP16+GP17+GP18+GP19+GP20+GP21+GP22+GP23+GP24 
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Supplementary Table 4. Derived glycan traits in five populations used for HILIC-UPLC analysis of IgG glycosylation.  
 Cohort Min. 1st Qu. Median Mean 3rd Qu. Max. 
Agalactosylation China 9,232 16,45 19,96 20,46 23,5 48,04 
Croatia 8,679 21,88 27,06 27,33 32,53 55,42 
Estonia 10,62 31,26 36,24 36,31 41,14 72,63 
Scotland 8,727 18,93 24,03 24,67 29,72 60,62 
England 7,458 19,21 24,6 25,29 30,52 63,45 
Monogalactosylation China 27,24 33,38 35,04 34,82 36,44 42,06 
Croatia 20,18 29,07 30,76 30,58 32,4 39,36 
Estonia 17,39 32,57 34,29 33,99 35,78 45,23 
Scotland 23,51 34,01 35,62 35,43 37,12 44,54 
England 22,7 34,68 36,21 36,02 37,55 49,37 
Digalactosylation China 7,297 19,07 21,86 21,76 24,6 33,82 
Croatia 4,603 11,33 13,75 14,26 16,72 29,7 
Estonia 3,129 10,32 12,43 12,69 14,8 26,02 
Scotland 5,246 14,09 17,12 17,52 20,65 35,39 
England 4,536 14,49 17,9 18,12 21,63 35,39 
Bisecting GlcNAc China 8,992 14,17 15,58 15,79 17,18 26,98 
Croatia 11,1 16,82 18,4 18,49 19,99 29,32 
Estonia 5,771 16,56 18,17 18,32 19,87 29,48 
Scotland 8,377 14,88 16,45 16,71 18,46 36,53 
England 6,958 15,24 16,96 17,17 18,9 32,23 
Sialylation China 12,3 20,62 22,92 22,95 25,37 33,51 
Croatia 13,32 24,26 27,33 27,83 30,93 51,82 
Estonia 4,63 14,97 16,74 17 18,82 39,29 
Scotland 10,3 19,62 22,16 22,37 25,05 36,94 
England 3,008 17,87 20,35 20,58 23,23 49,82 
Core fucosylation China 88,18 94,62 95,44 95,26 96,14 98,08 
Croatia 68,12 87,45 89,86 89,12 91,72 96,01 
Estonia 90,59 95,67 96,38 96,18 96,92 99,13 
Scotland 74 95,28 96,05 95,83 96,64 98,17 
England 81,95 94,74 95,59 95,36 96,28 98,14 
In table are given: analysed population, glycan trait parameters (minimum, maximum, median, mean, 1st and 3rd quartile). 
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Supplementary Table 5. Linear mixed model in five populations with age and sex defined as fixed effects and country 
of residence as a random effect. 
Derived glycan trait 
Percent of glycan trait 
variability explained by 
country of residence (%) 
Percent of glycan 
trait variability 
explained by age (%) 
Percent of glycan 
trait variability 
explained by sex (%) 
Country of 
residence P value 
Agalactosylation 14.4 30.9 0.8 6.6 × 10-194 
Monogalactosylation 39.9 0.0 0.2 < 6 × 10-350 
Digalactosylation 19.5 30.2 0.7 1.1 × 10-301 
Bisecting GlcNAc 6.3 20.1 0.1 6.7 × 10-104 
Sialylation 42.5 11.9 0.2 < 6 ×10-350 
Core fucosylation 57.5 0.1 0.0 < 6 ×10-350 
Displayed values represent percentage (%) glycan trait variability explained by age, sex and country of residence, with country 
of residence likelihood-ratio test P value. 
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Supplementary Table 6. Demographic characteristics of 27 populations used for IgG Fc glycosylation analysis.  
Population Country of residence 
Cohort 
abbreviation Min. Q1 Median Mean Q3 Max. F M 
Evenk minority China Evenk 10 22 29 33 41 85 29 58 
General population 
of China (Han) China China 20 26 44 40 51 60 58 42 
Kazak minority China ChiKaz 21 33 45 44 56 78 52 45 
Kyrgyz minority China ChiKrz 22 55 65 62 70 92 56 41 
Uyghur minority China ChiUyg 8 38 49 47 59 85 63 36 
Yakut minority Russia Yakut 18 34 42 44 54 72 72 28 
General population 
of Croatia Croatia Croatia 18 38 49 50 62 81 24 73 
Roma minority Croatia Roma 18 28 37 38 42 79 48 51 
General population 
of Germany Germany Germany 32 43 47 49 57 70 30 67 
General population 
of Italy Italy Italy 24 34 46 47 58 86 48 41 
General population 
of Kosovo Kosovo Kosovo 21 33 46 44 57 62 60 40 
General population 
of Papua New 
Guinea 
Papua 
New 
Guinea 
NewGui 3 8 12 18 26 48 46 37 
General population 
of Russia Russia Russia 9 17 20 23 26 43 62 38 
Kazak minority Russia RuKaz 21 34 42 43 53 63 48 50 
Tatar minority Russia RuTar 18 23 31 31 36 48 57 42 
Yakut minority Russia RuYak 20 37 47 47 56 75 68 13 
General population 
of Sweden Sweden Sweden 22 33 44 42 51 64 43 54 
Uninfected HIV 
cohort participants 
from Thailand 
Thailand Thailand 18 28 32 33 36 49 49 50 
General population 
of Trinidad and 
Tobago 
Trinidad 
and 
Tobago 
TriTob 22 40 53 50 59 77 81 15 
General population 
of Turkey Turkey Turkey 16 48 59 57 67 79 38 62 
General population 
of Uganda Uganda Uganda 17 29 33 33 37 47 54 44 
General population 
of England 
(SABRE cohort) 
England SabEng 59 63 67 68 72 77 26 72 
General population 
of England 
(TwinsUK cohort) 
England TwinsUK 21 33 46 46 57 70 55 42 
British Indians 
(SABRE cohort) England SabInd 60 65 69 69 73 83 22 76 
British Jamaicans 
(SABRE cohort) England SabJam 59 66 69 69 73 81 56 40 
Population of 
Orkney Islands Scotland Orkney 21 33 46 45 56 70 52 26 
Population of 
Shetland Islands Scotland Shetland 21 34 46 45 56 69 50 49 
In table are given: country of residence of participants, abbreviation of analysed cohort, age parameters (minimum, 
maximum, median, mean, 1st and 3rd quartile) and sex parameters (number of female and male participants). 
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Please browse Full Text version to see the data of Supplementary Tables 7–10.  
 
Supplementary Table 7. Derived glycan traits in 27 populations used for IgG1 Fc glycopeptide analysis.  
Supplementary Table 8. Derived glycan traits in 27 populations used for IgG2 Fc glycopeptide analysis.  
Supplementary Table 9. Derived glycan traits in 27 populations used for IgG4 Fc glycopeptide analysis.  
Supplementary Table 10. Correlations of IgG Fc derived glycan traits with participant’s country of residence 
development indicators.  
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Supplementary Table 11. Health-related Sustainable Development Goals (SDG) indicators used for assessment of  
country development level [65]. Development indicator and short descriptions are given. 
Health-related SDG indicator Definition 
SDG Overall health-related SDG index (health-related SDG indicators included) 
MDG Overall health-related MDX index (Health-related SDG indicators included in the Millennium Development Goals) 
non-MDG Health-related SDG indicators not included in the Millennium Development Goals 
Adolescent birth rate Birth rates for women aged 10–14 years and women aged 15–19 years, number of livebirths per 1000 women aged 10–14 years and women aged 15–19 years 
Air pollution mortality Age-standardised death rate attributable to household air pollution and ambient air pollution, per 100 000 population 
Alcohol Risk-weighted prevalence of alcohol consumption, as measured by the SEV for alcohol use, % 
Disaster Age-standardised death rate due to exposure to forces of nature, per 100 000 population 
Family planning need met, modern 
contraception 
Proportion of women of reproductive age (15–49 years) who have their need for family 
planning satisfied with modern methods, % women aged 15–49 years 
Hepatitis B Age-standardised rate of hepatitis B incidence, per 100 000 population 
HIV Age-standardised rate of new HIV infections, per 1000 population 
Household air pollution Risk-weighted prevalence of household air pollution, as measured by the SEV for household air pollution, % 
Hygiene Risk-weighted prevalence of populations with unsafe hygiene (no handwashing with soap), as measured by the SEV for unsafe hygiene, % 
Intimate partner violence Age-standardised prevalence of women aged 15 years and older who experienced intimate partner violence, %women aged 15 years and older 
Malaria Age-standardised rate of malaria cases, per 1000 population 
Maternal mortality ratio Maternal deaths per 100 000 livebirths 
Mean PM 2.5 Population-weighted mean levels of PM2.5, μg/m3 
NCDs Age-standardised death rate due to cardiovascular disease, cancer, diabetes, and chronic respiratory disease in populations aged 30 - 70 years, per 100 000 population 
Neglected tropical diseases Age-standardised prevalence of neglected tropical diseases, per 100 000 population 
Neonatal mortality Probability of dying during the first 28 days of life per 1000 livebirths 
Occupational risk burden Age-standardised all-cause DAILY rate attributable to occupational risks, per 100 000 population 
Overweight Prevalence of overweight in children aged 2 - 4 years, % 
Poisons Age-standardised death rate due to unintentional poisonings, per 100 000 population 
Road injuries Age-standardised death rate due to road traffic injuries, per 100 000 population 
Sanitation Risk-weighted prevalence of populations using unsafe or unimproved sanitation, as measured by the SEV for unsafe sanitation, % 
Skilled birth attendance Proportion of births attended by skilled health personnel (doctors, nurses, midwives, or country-specific medical staff [e.g., clinical officers]), % 
Smoking Age-standardised prevalence of daily smoking in populations aged 10 years and older, % population aged 10 years and older 
Stunting Prevalence of stunting in achieving, by 2025, the internationally agreed targets on children under age 5 years, % 
Suicide Age-standardised death rate due to self-harm, per 100 000 population 
Tuberculosis Age-standardised rate of new and relapsed tuberculosis cases, per 1000 population 
Under-5 mortality Probability of dying before age 5 years per 1000 livebirths 
Universal health coverage tracer Coverage of universal health coverage tracer interventions for prevention and treatment services, % 
Violence Age-standardised death rate due to interpersonal violence, per 100 000 population 
War Age-standardised death rate due to collective violence and legal intervention, per 100 000 population 
WaSH mortality Age-standardised death rate attributable to unsafe WaSH, per 100 000 population 
Wasting Prevalence of wasting in children under age 5 years, % 
Water Risk-weighted prevalence of populations using unsafe or unimproved water sources, as measured by the SEV for unsafe water, % 
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Supplementary Table 12. United Nation’s Human Development Index (HDI) indicators used for assessment of 
country development level [66].  
HDI indicator Definition 
HDI index Composite measure of three life dimensions: life expectancy, per capita income and 
education 
Health index Life expectancy at birth in 2014; expressed as an index using a minimum value of 20 
years and a maximum value of 85 years  
Life expectancy at birth Number of years a new-born infant could expect to live if prevailing patterns of age-
specific mortality rates at the time of birth stay the same throughout the infant’s life 
Education index Education index is an average of mean years of schooling (of adults) and expected years 
of schooling (of children) in 2014, both expressed as an index obtained by scaling with 
the corresponding maxima 
GDP Gross domestic product (GDP) per capita in 2013 
Life expectancy - M Life expectancy at birth, male (years) 
Life expectancy - F Life expectancy at birth, female (years) 
Water (UN) Accessibility of drinkable tap water 
Sanitation (UN) Accessibility of advanced sanitation 
Development indicator and short descriptions are given. 
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Supplementary Table 13. Development level of 14 countries expressed through 45 indicators.  
 China Thailand Sweden Germany England Scotland Croatia Italy Kosovo Russia Turkey Uganda Trinidad Papua 
SDG index 60 56 85 80 82 82 70 78 65 54 58 31 67 36 
Disaster 39 29 100 100 100 100 100 61 40 57 33 53 100 32 
Stunting 87 85 100 100 100 100 91 100 91 85 86 55 95 51 
Wasting 91 84 100 100 100 100 88 100 87 90 96 82 87 86 
Overweight 62 71 51 47 64 64 46 39 65 46 65 82 81 71 
MMR 62 61 79 71 70 70 71 79 68 61 64 28 46 22 
SBA 97 99 100 100 99 99 99 99 99 99 94 68 100 65 
Under-5 
mort 66 81 94 89 84 84 85 91 75 72 61 32 58 42 
NN mort 69 80 94 91 85 85 84 90 76 75 59 34 51 47 
HIV 46 34 65 57 51 51 69 54 57 32 64 15 35 35 
Tuberculosis 45 45 82 86 74 74 69 87 70 41 69 29 62 48 
Malaria 94 26 100 100 100 100 100 100 100 100 100 5 100 6 
Hepatitis B 40 33 85 85 85 85 66 82 66 49 43 33 67 21 
NTDs 89 87 100 100 100 100 100 100 100 99 97 85 98 54 
NCDs 58 61 87 77 78 78 62 85 54 41 73 46 47 19 
Suicide 59 42 51 55 64 64 47 71 44 21 81 43 46 42 
Alcohol 74 74 57 54 57 57 54 68 59 7 90 58 65 87 
Road 
injuries 49 36 94 88 94 94 72 75 69 53 66 35 55 37 
FP need met 86 66 91 92 95 95 34 86 37 75 70 41 76 47 
Adol birth 
rate 69 54 84 86 73 73 80 87 70 67 61 24 60 44 
UHC Tracer 81 69 99 96 100 100 84 97 84 85 82 69 93 45 
Air poll mort 48 61 96 83 83 83 68 83 58 62 71 33 74 28 
WaSH mort 75 49 87 84 77 77 88 96 88 79 76 22 64 21 
Poisons 50 69 71 94 75 75 84 81 73 47 80 37 71 44 
Smoking 52 60 75 46 55 55 32 52 43 41 47 87 68 36 
IPV 96 57 80 70 80 80 91 66 82 64 53 18 73 69 
Water 500 34 100 100 100 100 81 100 74 86 29 26 47 14 
Sanitation 66 98 100 100 100 100 97 100 85 79 87 20 90 20 
Hygiene 38 46 95 89 93 93 43 86 43 69 28 3 53 16 
HH air poll 79 88 100 100 100 100 94 100 78 98 98 2 100 55 
Occ risk 
burden 43 54 81 71 74 74 63 72 60 67 57 31 73 9 
Mean PM 2.5 25 46 81 62 65 65 51 53 51 58 37 24 62 62 
Violence 69 34 74 81 86 86 72 77 55 25 58 39 19 36 
War 100 100 100 100 100 100 100 100 100 31 19 100 100 100 
MDG index 70 63 94 92 90 90 80 92 76 75 67 33 69 33 
Non-MDG 
index 55 54 80 73 78 78 64 70 60 46 54 29 67 37 
HDI index 73 73 91 92 91 91 82 87 77 80 76 48 77 51 
Life exp 76 74 82 81 81 81 77 83 75 70 75 59 70 63 
Life exp F 78 78 84 83 83 83 81 86 78 76 79 61 74 65 
Life exp M 75 71 81 79 79 79 74 81 72 65 72 57 67 61 
GDP 11525 13932 43741 43207 37017 37017 20063 34167 12893 23564 18660 1368 29469 2458 
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Education 
index 61 62 84 89 89 89 78 78 75 81 66 45 71 41 
Health Index 86 84 96 94 93 93 88 97 85 77 85 59 78 66 
Water (UN) 96 98 100 100 100 100 100 100 99 97 100 79 95 40 
Sanitation 
(UN) 77 93 99 99 99 99 97 100 96 72 95 19 92 19 
Higher indicator value suggests better conditions impacting on human well-being in a given country. Indicator descriptions 
are given in Supplementary Tables 11 and 12. 
*MMR = maternal mortality ratio; SBA = skilled birth attendance; Under-5 mort = Under-5 mortality; NN mort = neonatal 
mortality; NTDs = neglected tropical diseases; NCDs = non-communicable diseases; FP need met = family planning need 
met, modern contraception; Adol birth rate = adolescent birth rate; UHC = universal health coverage; Air poll mort = air 
pollution mortality; WaSH Mort = water, sanitation, and hygiene mortality; IPV = intimate partner violence; HH air poll = 
household air pollution; MDG index = Millennium Development Goals Index; non-MDG index = health-related Sustainable 
Development Goals not included in MDG; HDI = Human Development Index; Life exp = Life expectancy at birth; Life exp  
F = Life expectancy – F; Life exp M = Life expectancy – M. 
 
Please browse Full Text version to see the data of Supplementary Table 14.  
 
Supplementary Table 14. Correlation between used development indicators. 
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Supplementary Table 15. Description of directly measured subclass-specific Fc IgG glycan traits measured by LC-MS 
with mass list. 
Glycan 
trait1 
 
IgG1 glycopeptide m/z3 IgG2&3 glycopeptide m/z4 IgG4glycopeptide m/z
5 Glycan trait description Glycan trait calculation6 
[M+2H]2+ [M+3H]3+ [M+2H]2+ [M+3H]3+ [M+2H]2+ [M+3H]3+ 
G0F 
 1317,527 878,687 1301,532 868,024 1309,529 873,356 Fraction of FA2 glycan in total  subclass Fc glycans 
G0F/total subclass Fc 
glycans*100 
G1F  1398,553 932,705 1382,558 922,042 1390,556 927,373 Fraction of FA2G1 glycan in total  subclass Fc glycans 
G1F/total subclass Fc 
glycans*100 
G2F  1479,58 986,722 1463,585 976,059 1471,582 981,391 Fraction of FA2G2 glycan in total  subclass Fc glycans 
G2F/total subclass Fc 
glycans*100 
G0FN  1419,067 946,38 1403,072 935,717 1411,069 941,049 Fraction of FA2B glycan in total  subclass Fc glycans 
G0FN/total subclass Fc 
glycans*100 
G1FN  1500,093 1000,398 1484,098 989,735 1492,096 995,066 Fraction of FA2BG1 glycan in total  subclass Fc glycans 
G1FN/total subclass Fc 
glycans*100 
G2FN  1581,119 1054,416 1565,125 1043,752 1573,122 1049,084 Fraction of FA2BG2 glycan in total  subclass Fc glycans 
G2FN/total subclass Fc 
glycans*100 
G1FS1  1544,101 1029,737 1528,106 1019,073 1536,104 1024,405 Fraction of FA2G1S1 glycan in total  subclass Fc glycans 
G1FS1/total subclass Fc 
glycans*100 
G2FS1  1625,127 1083,754 1609,133 1073,091 1617,13 1078,423 Fraction of FA2G2S1 glycan in total  subclass Fc glycans 
G2FS1/total subclass Fc 
glycans*100 
G1FNS1  1645,641 1097,430 1629,646 1086,767 1637,643 1092,098 Fraction of FA2BG1S1 glycan in total  subclass Fc glycans 
G1FNS1/total subclass 
Fc glycans*100 
G2FNS1  1726,667 1151,447 1710,672 1140,784 1718,67 1146,116 Fraction of FA2BG2S1 glycan in total  subclass Fc glycans 
G2FNS1/total subclass 
Fc glycans*100 
G0  1244,498 830,001 1228,503 819,338 1236,501 824,67 Fraction of A2 glycan in total  subclass Fc glycans 
G0/total subclass Fc 
glycans*100 
G1  1325,524 884,019 1309,529 873,356 1317,527 878,687 Fraction of A2G1 glycan in total  subclass Fc glycans 
G1/total subclass Fc 
glycans*100 
G2  1406,551 938,036 1390,556 927,373 1398,553 932,705 Fraction of A2G2 glycan in total  subclass Fc glycans 
G2/total subclass Fc 
glycans*100 
G0N  1346,038 897,694 1330,043 887,031 1338,04 892,363 Fraction of A2B glycan in total  subclass Fc glycans 
G0N/total subclass Fc 
glycans*100 
G1N  1427,064 951,712 1411,069 941,049 1419,067 946,38 Fraction of A2BG1 glycan in total  subclass Fc glycans 
G1N/total subclass Fc 
glycans*100 
G2N  1508,090 1005,730 1492,096 995,066 1500,093 1000,398 Fraction of A2BG2 glycan in total  subclass Fc glycans 
G2N/total subclass Fc 
glycans*100 
G1S1  1471,072 981,051 1455,077 970,387 1463,075 975,719 Fraction of A2G1S1 glycan in total  subclass Fc glycans 
G1S1/total subclass Fc 
glycans*100 
G2S1  1552,098 1035,068 1536,104 1024,405 1544,101 1029,737 Fraction of A2G2S1 glycan in total  subclass Fc glycans 
G2S1/total subclass Fc 
glycans*100 
G1NS1  1572,612 1048,744 1556,617 1038,081 1564,614 1043,412 Fraction of A2BG1S1 glycan in total  subclass Fc glycans 
G1NS1/total subclass Fc 
glycans*100 
G2NS1  1653,638 1102,761 1637,643 1092,098 1645,641 1097,43 Fraction of A2BG2S1 glycan in total  subclass Fc glycans 
G2NS1/total subclass Fc 
glycans*100 
1Glycan composition: N (N-acetylglucosamine), F (fucose), G (galactose) and S (N-acetylneuraminic acid) followed by a 
number representing the number and type of monosaccharides attached to A2 glycan. 
2Glycan structures are drawn in GlycoWorkbench version 2. blue square = N-acetylglucosamine, red triangle = fucose, green 
circle = mannose, yellow circle = galactose, purple diamond = N-acetylneuraminic acid. 
3IgG1 tryptic peptide sequence carrying glycan: E293EQYNSTYR301  
4IgG4 tryptic peptide sequence carrying glycan: E293EQFNSTFR301  
5IgG2&3 tryptic peptide sequence carrying glycan: E293EQFNSTYR301 
6total subclass Fc glycans = sum of all 20 glycopeptides in one IgG subclass 
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Supplementary Table 16. Description of derived subclass-specific Fc IgG glycan traits measured by LC-MS with mass 
list. 
Derived glycan 
trait Derived trait description Derived trait calculation 
Core fucosylation Fraction of structures containing core fucose in subclass specific Fc glycans 
G0F+G1F+G2F+G0FN+G1FN+G2FN+G1F
S1+G2FS1+G1FNS1+G2FNS1 
Bisecting GlcNAc Fraction of structures containing bisecting GlcNAc in subclass specific Fc glycans 
G0FN+G1FN+G2FN+G1FNS1+G2FNS1+
G0N+G1N+G2N+G1NS1+G2NS1 
Agalactosylation Fraction of agalactosylated structures in subclass specific Fc glycans G0+G0F+G0N+G0FN 
Monogalactosylation Fraction of structures containing one galactose in subclass specific Fc glycans 
G1F+G1FN+G1FS1+G1FNS1+G1+G1N+G
1S1+G1NS1 
Digalactosylation Fraction of structures containing two galactoses in subclass specific Fc glycans 
G2F+G2FN+G2FS1+G2FNS1+G2+G2N+G
2S1+G2NS1 
Sialylation Fraction of structures containing sialic acid in subclass specific Fc glycans 
G1FS1+G2FS1+G1FNS1+G2FNS1+G1S1+
G2S1+G1NS1+G2NS1 
 
Supplementary Table 17. Correlations between derived glycan traits measured by HILIC-UPLC. 
 Agalactosylation Monogalactosylation Digalactosylation Bisecting GlcNAc Sialylation Core fucosylation 
Agalactosylation 1,00 -0,23 -0,89 0,38 -0,70 0,17 
Monogalactosylation -0,23 1,00 0,21 -0,07 -0,41 0,56 
Digalactosylation -0,89 0,21 1,00 -0,39 0,43 0,04 
Bisecting GlcNAc 0,38 -0,07 -0,39 1,00 -0,23 -0,09 
Sialylation -0,70 -0,41 0,43 -0,23 1,00 -0,63 
Core fucosylation 0,17 0,56 0,04 -0,09 -0,63 1,00 
 
  
www.aging-us.com 15259 AGING 
Supplementary Table 18. Correlations between derived subclass-specific Fc IgG glycan traits measured by LC-MS. 
 
IgG
1_A
galactosylation 
IgG
1_M
onogalactosylation 
IgG
1_D
igalactosylation 
IgG
1_Sialylation 
IgG
1_Bisecting 
IgG
2_A
galactosylation 
IgG
2_M
onogalactosylation 
IgG
2_D
igalactosylation 
IgG
2_Sialylation 
IgG
2_Bisecting 
IgG
4_A
galactosylation 
IgG
4_M
onogalactosylation 
IgG
4_D
igalactosylation 
IgG
4_Sialylation 
IgG
4_Bisecting 
IgG1_Agalactosylation 1,00 -0,64 -0,90 -0,62 0,26 0,81 -0,63 -0,76 -0,57 0,21 0,67 -0,39 -0,62 -0,47 0,22 
IgG1_Monogalactosylation -0,64 1,00 0,47 -0,09 0,00 -0,42 0,65 0,29 0,08 -0,02 -0,33 0,50 0,22 0,02 -0,06 
IgG1_Digalactosylation -0,90 0,47 1,00 0,46 -0,30 -0,81 0,56 0,87 0,53 -0,26 -0,62 0,31 0,67 0,40 -0,23 
IgG1_Sialylation -0,62 -0,09 0,46 1,00 -0,26 -0,51 0,15 0,47 0,62 -0,17 -0,50 0,04 0,44 0,60 -0,19 
IgG1_Bisecting 0,26 0,00 -0,30 -0,26 1,00 0,28 -0,15 -0,31 -0,23 0,84 0,28 -0,12 -0,31 -0,19 0,60 
IgG2_Agalactosylation 0,81 -0,42 -0,81 -0,51 0,28 1,00 -0,72 -0,93 -0,77 0,28 0,61 -0,30 -0,60 -0,46 0,24 
IgG2_Monogalactosylation -0,63 0,65 0,56 0,15 -0,15 -0,72 1,00 0,56 0,20 -0,17 -0,44 0,41 0,39 0,18 -0,12 
IgG2_Digalactosylation -0,76 0,29 0,87 0,47 -0,31 -0,93 0,56 1,00 0,68 -0,28 -0,58 0,23 0,64 0,43 -0,23 
IgG2_Sialylation -0,57 0,08 0,53 0,62 -0,23 -0,77 0,20 0,68 1,00 -0,22 -0,46 0,10 0,42 0,50 -0,23 
IgG2_Bisecting 0,21 -0,02 -0,26 -0,17 0,84 0,28 -0,17 -0,28 -0,22 1,00 0,23 -0,11 -0,25 -0,15 0,58 
IgG4_Agalactosylation 0,67 -0,33 -0,62 -0,50 0,28 0,61 -0,44 -0,58 -0,46 0,23 1,00 -0,56 -0,91 -0,75 0,25 
IgG4_Monogalactosylation -0,39 0,50 0,31 0,04 -0,12 -0,30 0,41 0,23 0,10 -0,11 -0,56 1,00 0,34 -0,06 -0,39 
IgG4_Digalactosylation -0,62 0,22 0,67 0,44 -0,31 -0,60 0,39 0,64 0,42 -0,25 -0,91 0,34 1,00 0,69 -0,19 
IgG4_Sialylation -0,47 0,02 0,40 0,60 -0,19 -0,46 0,18 0,43 0,50 -0,15 -0,75 -0,06 0,69 1,00 0,00 
IgG4_Bisecting 0,22 -0,06 -0,23 -0,19 0,60 0,24 -0,12 -0,23 -0,23 0,58 0,25 -0,39 -0,19 0,00 1,00 
 
